
I-Mab (IMAB) Stock Forecast & Price Target
I-Mab (IMAB) Analyst Ratings
Bulls say
I-MAB's stock outlook is bolstered by the promising Phase 2 study results of uliledlimab, which demonstrated a favorable safety profile and an objective response rate (ORR) of 31% across all patients, indicating strong potential for success in treating solid tumors. Additionally, the encouraging Phase 1 pharmacokinetic/pharmacodynamic data reveal full target engagement for uliledlimab, showing a positive correlation between drug exposure and ORR in metastatic non-small cell lung cancer patients, adding to the bullish sentiment surrounding this program. Furthermore, Givastomig continues to demonstrate a favorable safety profile and favorable pharmacokinetics, suggesting that its ongoing development could significantly enhance I-MAB's valuation and present additional upside potential.
Bears say
I-Mab experienced a significant decrease in revenue, reporting no revenues in the third quarter of 2024, down from $0.31 million in the same period the previous year. The company's net losses have widened, showing a loss of $(20.5) million for the third quarter and $(38.9) million for the nine-month period ended September 30, 2024, compared to $(8.2) million and $(45.3) million respectively for the prior year. Additionally, the presence of serious treatment-related adverse events, along with the limited clinical utility of certain candidates due to toxicity issues, raises concerns about the viability and future success of its drug pipeline.
This aggregate rating is based on analysts' research of I-Mab and is not a guaranteed prediction by Public.com or investment advice.
I-Mab (IMAB) Analyst Forecast & Price Prediction
Start investing in I-Mab (IMAB)
Order type
Buy in
Order amount
Est. shares
0 shares